{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:51:29Z","timestamp":1783968689924,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jval.2015.11.009","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T21:30:44Z","timestamp":1451424644000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia"],"prefix":"10.1016","volume":"19","author":[{"given":"Dominic","family":"Tilden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.11.009_bib1","series-title":"Therapy with Botulinum Toxin","article-title":"Dystonia","author":"Fahn","year":"1994"},{"key":"10.1016\/j.jval.2015.11.009_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mds.870030302","article-title":"Epidemiology of focal and generalized dystonia in Rochester, Minnesota","volume":"3","author":"Nutt","year":"1988","journal-title":"Mov Disord"},{"key":"10.1016\/j.jval.2015.11.009_bib3","unstructured":"Australian Bureau of Statistics. 3101.0 Australian demographic statistics. December 2011. Available from: http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/allprimarymainfeatures\/81C5AE743DDCF8F0CA257A850013DF4C?opendocument. [Accessed September 15, 2014]."},{"key":"10.1016\/j.jval.2015.11.009_bib4","unstructured":"Medical Benefits Schedule (MBS) Online. Available from: http:\/\/www.mbsonline.gov.au\/. [Accessed March 12, 2015]."},{"key":"10.1016\/j.jval.2015.11.009_bib5","unstructured":"Pharmaceutical Benefits Scheme: Pharmaceutical Benefits Schedule (PBS). Available from: http:\/\/www.pbs.gov.au\/pbs\/home. [Accessed September 3, 2015]."},{"key":"10.1016\/j.jval.2015.11.009_bib6","series-title":"Botulinum Toxin in Urology","author":"Chancellor","year":"2011"},{"key":"10.1016\/j.jval.2015.11.009_bib7","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","article-title":"Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin","volume":"151","author":"Lee","year":"2005","journal-title":"Microbiology"},{"key":"10.1016\/j.jval.2015.11.009_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jval.2015.11.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2015.11.009_bib10","unstructured":"Therapeutic Goods Administration. Product information for BOTOX\u00ae botulinum toxin, type A purified neurotoxin complex 100U injection vial. Available from: www.tga.gov.au. [Accessed March 3, 2015]."},{"key":"10.1016\/j.jval.2015.11.009_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/14796708.2.5.485","article-title":"Efficacy and safety of botulinum neurotoxin type A free of complexing proteins (NT201) in cervical dystonia and blepharospasm","volume":"2","author":"Jost","year":"2007","journal-title":"Future Neurol"},{"key":"10.1016\/j.jval.2015.11.009_bib12","unstructured":"Merz Clinical Study Report MRZ60201-0003. Safety and Efficacy of NT 201 (Highly Purified Botulinum Neurotoxin A) Compared to BOTOX (Purified Botulinum Neurotoxin A-Complex) in Blepharospasm. Frankfurt am Main, Germany: Merz Pharmaceuticals, 2003."},{"key":"10.1016\/j.jval.2015.11.009_bib13","unstructured":"Merz Clinical Study Report MRZ60201-0013. Safety and Efficacy of NT 201 (Highly Purified Botulinum Neurotoxin A) Compared to BOTOX (Purified Botulinum Neurotoxin A-Complex) in Cervical Dystonia. Frankfurt am Main, Germany: Merz Pharmaceuticals, 2003."},{"key":"10.1016\/j.jval.2015.11.009_bib14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jval.2015.11.009_bib15","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin\u00ae) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jval.2015.11.009_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.71.2.193","article-title":"Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia","volume":"71","author":"Hilker","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jval.2015.11.009_bib17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxin A (NT201, Xeomin) in the treatment of blepharospasm\u2014a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jval.2015.11.009_bib18","doi-asserted-by":"crossref","first-page":"L103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT201, Xeomin, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jval.2015.11.009_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2014.08.004","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","volume":"346","author":"Evidente","year":"2014","journal-title":"J Neurol Sci"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515051293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515051293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T13:53:31Z","timestamp":1537106011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515051293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1098301515051293"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.11.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}